<p>Cerus Corporation (NASDAQ:CERS - 獲取免費報告) 在八月份的空頭頭寸大幅增加。截至 8 月 15 日，空頭頭寸總計為 9,740,000 股，比 7 月 31 日的 7,010,000 股增加了 38.9%。根據平均每日交易量 1,240,000 股，目前的覆蓋天數比率為 7.9 天。</p>
<h2>Cerus 的機構交易</h2>
<p>幾家大型投資者最近買賣了該公司的股票。Wasatch Advisors LP 在第二季度將其在 Cerus 的持股增加了 2.6%。Wasatch Advisors LP 目前擁有 8,533,758 股生物技術公司的股票，價值 12,033,000 美元，在上個季度又購買了 213,917 股。Millennium Management LLC 在第一季度將其在 Cerus 的持股增加了 12.0%。Millennium Management LLC 目前擁有 3,222,327 股生物技術公司的股票，價值 4,479,000 美元，在此期間又購買了 344,395 股。Acadian Asset Management LLC 在第二季度將其在 Cerus 的持股增加了 38.6%。Acadian Asset Management LLC 目前擁有 2,632,304 股生物技術公司的股票，價值 3,710,000 美元，在此期間又購買了 733,683 股。Ieq Capital LLC 在第二季度將其在 Cerus 的持股增加了 4.2%。Ieq Capital LLC 目前擁有 2,418,263 股生物技術公司的股票，價值 3,410,000 美元，在此期間又購買了 97,467 股。最後，Charles Schwab Investment Management Inc.在第一季度將其在 Cerus 的持股增加了 6.5%。Charles Schwab Investment Management Inc.目前擁有 1,774,137 股生物技術公司的股票，價值 2,466,000 美元，在此期間又購買了 107,771 股。機構投資者和對沖基金持有該公司 78.37% 的股票。</p>
<h2>Cerus 股票表現</h2>
<p>CERS 的股票在週一開盤價為 1.33 美元。該公司的市值為 2.5496 億美元，市盈率為-13.30，貝塔值為 1.63。該公司的債務與股本比率為 1.01，流動比率為 2.00，速動比率為 1.35。該公司的 50 日簡單移動平均線為 1.34 美元，200 日簡單移動平均線為 1.37 美元。Cerus 的 1 年最低價為 1.12 美元，1 年最高價為 2.24 美元。</p>
<p>Cerus (NASDAQ:CERS - 獲取免費報告) 最近於 8 月 5 日發佈了其財報。這家生物技術公司報告的每股收益（EPS）為-0.03 美元，低於分析師一致預期的-0.02 美元，差距為-0.01 美元。該公司在該季度的收入為 6010 萬美元，而分析師預期為 5180 萬美元。Cerus 的淨利潤率為-9.81%，股本回報率為-33.77%。Cerus 已將其 2025 財年的指引設定為每股收益。股票分析師預測 Cerus 在當前財年將發佈-0.08 的每股收益。</p>
<h2>關於 Cerus</h2>
<p>(獲取免費報告)</p>
<p>Cerus Corporation 是一家生物醫學產品公司。該公司專注於開發和商業化 INTERCEPT 血液系統，以增強血液安全性。其 INTERCEPT 血液系統是一種控制生物複製的專有技術，旨在減少用於輸血的捐贈血液成分中的血源性病原體。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Cerus</li>
<li>複利及其在投資中的重要性</li>
<li>2 只可能在美聯儲降息時暴漲的股票</li>
<li>想在下跌趨勢中獲利？下跌趨勢解析。</li>
<li>2025 年市場表現優於大盤的 3 只金融科技股票</li>
<li>內部交易可能不會告訴你你想的那樣</li>
<li>潛在的降息可能使這些公司受益</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Cerus 嗎？</h2>
<p>在你考慮 Cerus 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Cerus 並不在名單上。</p>
<p>雖然 Cerus 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CERS

<p>Cerus Corporation（納斯達克代碼：CERS）在八月份的空頭頭寸顯著增加了 38.9%，截至 8 月 15 日，總計達到 9,740,000 股。根據每日平均交易量 1,240,000 股，覆蓋天數比率為 7.9 天。機構投資者持有該公司 78.37% 的股份，其中 Wasatch Advisors 和 Millennium Management 等公司的持股顯著增加。Cerus 報告的季度每股收益為（$0.03），未達到預期，但收入超出預期，達到 6010 萬美元。該股開盤價為$1.33，市值為 2.5496 億美元</p>

<p>Cerus Corporation (NASDAQ:CERS - Get Free Report) was the target of a large increase in short interest in the month of August. As of August 15th, there was short interest totaling 9,740,000 shares, anincreaseof38.9% from the July 31st total of 7,010,000 shares. Based on an average daily volume of 1,240,000 shares, the days-to-cover ratio is currently 7.9 days. Based on an average daily volume of 1,240,000 shares, the days-to-cover ratio is currently 7.9 days.</p>
<div class="lb-trans"><p>Cerus Corporation (NASDAQ:CERS - 獲取免費報告) 在八月份的空頭頭寸大幅增加。截至 8 月 15 日，空頭頭寸總計為 9,740,000 股，比 7 月 31 日的 7,010,000 股增加了 38.9%。根據平均每日交易量 1,240,000 股，目前的覆蓋天數比率為 7.9 天。</p>
</div><h2>Institutional Trading of Cerus</h2>
<div class="lb-trans"><h2>Cerus 的機構交易</h2>
</div><p>Several large investors have recently bought and sold shares of the company. Wasatch Advisors LP grew its position in shares of Cerus by 2.6% during the second quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company's stock worth $12,033,000 after buying an additional 213,917 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Cerus by 12.0% in the 1st quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company's stock valued at $4,479,000 after buying an additional 344,395 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of Cerus by 38.6% in the 2nd quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company's stock valued at $3,710,000 after buying an additional 733,683 shares during the period. Ieq Capital LLC boosted its holdings in shares of Cerus by 4.2% during the second quarter. Ieq Capital LLC now owns 2,418,263 shares of the biotechnology company's stock valued at $3,410,000 after acquiring an additional 97,467 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Cerus by 6.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,774,137 shares of the biotechnology company's stock valued at $2,466,000 after acquiring an additional 107,771 shares during the period. Institutional investors and hedge funds own 78.37% of the company's stock.</p>
<div class="lb-trans"><p>幾家大型投資者最近買賣了該公司的股票。Wasatch Advisors LP 在第二季度將其在 Cerus 的持股增加了 2.6%。Wasatch Advisors LP 目前擁有 8,533,758 股生物技術公司的股票，價值 12,033,000 美元，在上個季度又購買了 213,917 股。Millennium Management LLC 在第一季度將其在 Cerus 的持股增加了 12.0%。Millennium Management LLC 目前擁有 3,222,327 股生物技術公司的股票，價值 4,479,000 美元，在此期間又購買了 344,395 股。Acadian Asset Management LLC 在第二季度將其在 Cerus 的持股增加了 38.6%。Acadian Asset Management LLC 目前擁有 2,632,304 股生物技術公司的股票，價值 3,710,000 美元，在此期間又購買了 733,683 股。Ieq Capital LLC 在第二季度將其在 Cerus 的持股增加了 4.2%。Ieq Capital LLC 目前擁有 2,418,263 股生物技術公司的股票，價值 3,410,000 美元，在此期間又購買了 97,467 股。最後，Charles Schwab Investment Management Inc.在第一季度將其在 Cerus 的持股增加了 6.5%。Charles Schwab Investment Management Inc.目前擁有 1,774,137 股生物技術公司的股票，價值 2,466,000 美元，在此期間又購買了 107,771 股。機構投資者和對沖基金持有該公司 78.37% 的股票。</p>
</div><h2>Cerus Stock Performance</h2>
<div class="lb-trans"><h2>Cerus 股票表現</h2>
</div><p>Shares of CERS opened at $1.33 on Monday. The stock has a market cap of $254.96 million, a price-to-earnings ratio of -13.30 and a beta of 1.63. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.00 and a quick ratio of 1.35. The firm has a 50 day simple moving average of $1.34 and a 200-day simple moving average of $1.37. Cerus has a 1-year low of $1.12 and a 1-year high of $2.24.</p>
<div class="lb-trans"><p>CERS 的股票在週一開盤價為 1.33 美元。該公司的市值為 2.5496 億美元，市盈率為-13.30，貝塔值為 1.63。該公司的債務與股本比率為 1.01，流動比率為 2.00，速動比率為 1.35。該公司的 50 日簡單移動平均線為 1.34 美元，200 日簡單移動平均線為 1.37 美元。Cerus 的 1 年最低價為 1.12 美元，1 年最高價為 2.24 美元。</p>
</div><p>Cerus (NASDAQ:CERS - Get Free Report) last released its earnings results on Tuesday, August 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). The firm had revenue of $60.10 million during the quarter, compared to analysts' expectations of $51.80 million. Cerus had a negative net margin of 9.81% and a negative return on equity of 33.77%. Cerus has set its FY 2025 guidance at EPS. Equities analysts forecast that Cerus will post -0.08 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Cerus (NASDAQ:CERS - 獲取免費報告) 最近於 8 月 5 日發佈了其財報。這家生物技術公司報告的每股收益（EPS）為-0.03 美元，低於分析師一致預期的-0.02 美元，差距為-0.01 美元。該公司在該季度的收入為 6010 萬美元，而分析師預期為 5180 萬美元。Cerus 的淨利潤率為-9.81%，股本回報率為-33.77%。Cerus 已將其 2025 財年的指引設定為每股收益。股票分析師預測 Cerus 在當前財年將發佈-0.08 的每股收益。</p>
</div><h2>About Cerus</h2>
<div class="lb-trans"><h2>關於 Cerus</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.</p>
<div class="lb-trans"><p>Cerus Corporation 是一家生物醫學產品公司。該公司專注於開發和商業化 INTERCEPT 血液系統，以增強血液安全性。其 INTERCEPT 血液系統是一種控制生物複製的專有技術，旨在減少用於輸血的捐贈血液成分中的血源性病原體。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Cerus</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>2 Stocks That Could Rocket on a Fed Rate Cut</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>3 Fintech Stocks Beating the Market in 2025</li>
<li>Insider Trades May Not Tell You What You Think</li>
<li>Potential Rate Cuts Could Benefit These Firms</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Cerus</li>
<li>複利及其在投資中的重要性</li>
<li>2 只可能在美聯儲降息時暴漲的股票</li>
<li>想在下跌趨勢中獲利？下跌趨勢解析。</li>
<li>2025 年市場表現優於大盤的 3 只金融科技股票</li>
<li>內部交易可能不會告訴你你想的那樣</li>
<li>潛在的降息可能使這些公司受益</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cerus Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Cerus 嗎？</h2>
</div><p>Before you consider Cerus, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Cerus 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cerus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Cerus 並不在名單上。</p>
</div><p>While Cerus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cerus 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Cerus 公司（NASDAQ:CERS）在八月份的空頭頭寸增長了 38.9%